soul trial oral semaglutide cardiovascular outcomes nejm 2024 2025 reduced the risk of clinically important kidney and death from (CV) causes in patients with type 2 diabetes (T2D) and CKD ca. #ERA24 🇸🇪 #Nephpearls https://www.nejm .org/doi/full/10.1056/NEJMoa2403347 Oral Semaglutide Cuts Cardiovascular Risk

Dosage and frequency determined based on individual condition severity

I filed a patent to use GLP-1 as an anxiolytic, but really, the mice were just sick patft.uspto.gov/netacgi/nph-Pa The CNS GLP-1 food intake #weightloss #obesity story has turned out to be far more scientifically interesting and clinically relevant than I first appreciated

doi:10.1016/S0891-5849(99)00090-8.

TB-500 at a Glance BPC-157 and TB-500 are both commonly discussed as recovery peptides, but they are not interchangeable

These results indicated that the administration of 2APB effectively inhibited the transmission of oxidative stress molecules by hepatocyte GJs and impacted oxidative stress in the liver

Regular check-ups and blood tests can determine if there is a deficiency